MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 - Germany

This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

: Unerwünschtes Ereignis - Oxaliplatin-induzierte Neuropathie

Raw json | Download

{
  "resourceType" : "AdverseEvent",
  "id" : "mii-exa-onko-oxaliplatin-neuropathy",
  "language" : "de",
  "text" : {
    "status" : "generated",
    "div" : "<div xml:lang=\"de\" lang=\"de\"><hr/><p><b>German</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: AdverseEvent mii-exa-onko-oxaliplatin-neuropathy</b></p><a name=\"de-mii-exa-onko-oxaliplatin-neuropathy\"> </a><a name=\"de-hcmii-exa-onko-oxaliplatin-neuropathy\"> </a><p><b>actuality</b>: Adverse Event</p><p><b>event</b>: <span title=\"Codes:{https://www.meddra.org 10034620}\">Oxaliplatin-induced peripheral neuropathy, grade 3 (CTCAE v5.0)</span></p><p><b>subject</b>: <a href=\"Patient-example-modification.html\">Martin Beispiel  Male, DoB: 1958-11-03</a></p><p><b>date</b>: 2024-06-10</p><p><b>detected</b>: 2024-06-05</p><p><b>recordedDate</b>: 2024-06-10</p><p><b>seriousness</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/adverse-event-seriousness non-serious}\">Non-serious</span></p><p><b>severity</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/adverse-event-severity severe}\">Severe</span></p><blockquote><p><b>suspectEntity</b></p><p><b>instance</b>: <a href=\"MedicationStatement-mii-exa-onko-modification-oxaliplatin-phase1.html\">MedicationStatement: status = stopped; statusReason = Adverse reaction (disorder); medication[x] = Oxaliplatin; effective[x] = 2024-03-15 --&gt; 2024-06-10; note = FOLFOX4 - Cycles 1-6 only. Discontinued due to severe peripheral neuropathy. Patient experienced numbness and tingling in hands and feet (grade 3 CTCAE), interfering with daily activities.</a></p><h3>Causalities</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Assessment</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/adverse-event-causality-assess certain}\">Certain</span></td></tr></table></blockquote></div>"
  },
  "actuality" : "actual",
  "event" : {
    "coding" : [
      {
        "system" : "https://www.meddra.org",
        "code" : "10034620",
        "display" : "Peripheral sensory neuropathy"
      }
    ],
    "text" : "Oxaliplatin-induced peripheral neuropathy, grade 3 (CTCAE v5.0)"
  },
  "subject" : {
    🔗 "reference" : "Patient/example-modification"
  },
  "date" : "2024-06-10",
  "detected" : "2024-06-05",
  "recordedDate" : "2024-06-10",
  "seriousness" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/adverse-event-seriousness",
        "code" : "non-serious"
      }
    ]
  },
  "severity" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/adverse-event-severity",
        "code" : "severe",
        "display" : "Severe"
      }
    ]
  },
  "suspectEntity" : [
    {
      "instance" : {
        🔗 "reference" : "MedicationStatement/mii-exa-onko-modification-oxaliplatin-phase1"
      },
      "causality" : [
        {
          "assessment" : {
            "coding" : [
              {
                "system" : "http://terminology.hl7.org/CodeSystem/adverse-event-causality-assess",
                "code" : "certain",
                "display" : "Certain"
              }
            ]
          }
        }
      ]
    }
  ]
}